11:19 AM EST - BriaCell Therapeutics Corp. : Has approved a consolidation of the Company's issued and outstanding common shares on the basis of 300 pre-consolidation shares for one post-consolidated share. The purpose of the Consolidation is to facilitate the Company’s ability to list on a recognized stock exchange in the United States of America. The effective date for the Consolidation will be January 2, 2020. BriaCell Therapeutics Corp.
shares V.BCT are trading unchanged at $0.05.
